Vyne Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $14.24 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Vyne Therapeutics Inc had its IPO on 2018-01-25 under the ticker symbol VYNE.
The company operates in the Healthcare sector and Biotechnology industry. Vyne Therapeutics Inc has a staff strength of 12 employees.
Shares of Vyne Therapeutics Inc opened at $4.06 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.05 - $4.2, and closed at $4.08.
This is a -0.97% slip from the previous day's closing price.
A total volume of 9,709 shares were traded at the close of the day’s session.
In the last one week, shares of Vyne Therapeutics Inc have slipped by -5.99%.
Vyne Therapeutics Inc's Key Ratios
Vyne Therapeutics Inc has a market cap of $14.24 million, indicating a price to book ratio of 0.2433 and a price to sales ratio of 0.6757.
In the last 12-months Vyne Therapeutics Inc’s revenue was $407000 with a gross profit of $477000 and an EBITDA of $-33458000. The EBITDA ratio measures Vyne Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Vyne Therapeutics Inc’s operating margin was -8233.42% while its return on assets stood at -52.26% with a return of equity of -99.55%.
In Q2, Vyne Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 7.1%.
Vyne Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-10.06 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vyne Therapeutics Inc’s profitability.
Vyne Therapeutics Inc stock is trading at a EV to sales ratio of 0.0207 and a EV to EBITDA ratio of 0.5172. Its price to sales ratio in the trailing 12-months stood at 0.6757.
Vyne Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $24.96 million
- Total Liabilities
- $6.37 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Vyne Therapeutics Inc ended 2023 with $24.96 million in total assets and $0 in total liabilities. Its intangible assets were valued at $24.96 million while shareholder equity stood at $17.27 million.
Vyne Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $6.37 million in other current liabilities, in common stock, $-678564000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $20.63 million and cash and short-term investments were $20.63 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Vyne Therapeutics Inc’s total current assets stands at $22.96 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $234000.00 compared to accounts payable of $1.16 million and inventory worth $67000.00.
In 2023, Vyne Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Vyne Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Vyne Therapeutics Inc stock is currently trading at $4.08 per share. It touched a 52-week high of $8.73 and a 52-week low of $8.73. Analysts tracking the stock have a 12-month average target price of $36.33.
Its 50-day moving average was $4.53 and 200-day moving average was $4.32 The short ratio stood at 2.99 indicating a short percent outstanding of 0%.
Around 140.4% of the company’s stock are held by insiders while 1108% are held by institutions.
Frequently Asked Questions About Vyne Therapeutics Inc
Similar Industry Stocks (Biotechnology)
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company’s lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.